TyG Index Levels in Klinefelter Syndrome

Endothelial Dysfunction Clinical Trial

Official title:

Triglyceride-Glucose Index Levels in Patients With Klinefelter Syndrome and Its Relationship With the Endothelial Dysfunction and Insulin Resistance: A Cross-sectional Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05014997
• Other study ID #: GMS_21
• Status: Completed
• Start date: February 10, 2013
• Est. completion date: March 1, 2017

Study information

• Verified date: August 2021
• Source: Gulhane School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

It is well known that the frequency of cardiometabolic diseases are increased in patients with Klinefelter Syndrome. The triglyceride-glucose index (TyG index) is a simple surrogate marker of insulin resistance and is also associated with various cardiometabolic diseases. The aim of this study to investigate the TyG index levels and its relationship with insulin resistance and endothelial dysfunction in patients with KS.

Description:

From the patient database of our Endocrinology department we randomly included a total of 30 patients with KS and 32 healthy controls in the study. All the recorded data in the database were registered under the approval of Local Ethical Committee of Gulhane School of Medicine.

The clinical and laboratory parameters, TyG index, asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA-IR) and high-sensitivity C-reactive protein (hs-CRP) levels were gathered from the database and the triglyceride-glucose index was calculated by the help of pre-measured laboratory parameters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 1, 2017
• Est. primary completion date: October 1, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 28 Years

Eligibility

Inclusion Criteria:

• Patients with a verified Klifelter Syndrome karyotype (all subjects included were 47, XXY) and who were not previously given testosterone replacement.

Exclusion Criteria:

• age <18 years,

• acute infection, malignancy, any visceral organ dysfunction, nutritional derangements, clinical history of cardiovascular disease, cerebrovascular disease, drug use such as antidiabetic or lipid-lowering medications, or those lacking complete clinical data.

Related Conditions & MeSH terms

• Cardiac Event
• Endothelial Dysfunction
• Klinefelter Syndrome
• Syndrome

Intervention

Other:
• no intervention
this study was designed as retrospective observational study

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gulhane School of Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiometabolic risk	Triglyceride - Glucose Index	1 day